Jacobs Levy Equity Management, Inc Inhibrx, Inc. Transaction History

Jacobs Levy Equity Management, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$8.52 - $25.26 $109,098 - $323,454	-12,805 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$19.89 - $43.18 $38,467 - $83,510	-1,934 Reduced 13.12%	12,805 $285,000
Q4 2021 Feb 14, 2022	BUY	$26.75 - $46.02 $38,734 - $66,636	1,448 Added 10.89%	14,739 $644,000
Q3 2021 Nov 15, 2021	SELL	$25.18 - $37.81 $487,812 - $732,493	-19,373 Reduced 59.31%	13,291 $443,000
Q2 2021 Aug 16, 2021	BUY	$14.69 - $27.52 $32,949 - $61,727	2,243 Added 7.37%	32,664 $899,000

Q1 2021 May 17, 2021	BUY	$16.27 - $41.26 $494,949 - $1.26 Million	30,421 New	30,421 $611,000

132

35.5M

64.8K

91.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $553M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.